Abstract
BackgroundColorectal cancer is a malignant gastrointestinal cancer, in which some advanced patients would develop cancer cachexia (CAC). CAC is defined as a multi-factorial syndrome characterized by weight loss and muscle loss (with or without fat mass), leading to progressive dysfunction, thereby increasing morbidity and mortality. ApcMin/+ mice develop spontaneous intestinal adenoma, which provides an established model of colorectal cancer for CAC study. Upon studying the ApcMin/+ mouse model, we observed a marked decrease in weight gain beginning around week 15. Such a reduction in weight gain was rescued when ApcMin/+ mice were crossed with MMP12−/− mice, indicating that MMP12 has a role in age-related ApcMin/+-associated weight loss. As a control, the weight of MMP12−/− mice on a weekly basis, their weight were not significantly different from those of WT mice.MethodsApcMin/+; MMP12−/− mice were obtained by crossing ApcMin/+ mice with MMP12 knockout (MMP12 −/−) mice. Histological scores were assessed using hematoxylin-eosin (H&E) staining. MMP12 expression was confirmed by immunohistochemistry and immunofluorescence staining. ELISA, protein microarrays and quantitative Polymerase Chain Reaction (qPCR) were used to investigate whether tumor could up-regulate IL-6. Cell-based assays and western blot were used to verify the regulatory relationship between IL-6 and MMP12. Fluorescence intensity was measured to determine whether MMP12 is associated with insulin and insulin-like growth factor 1 (IGF-1) in vitro. MMP12 inhibitors were used to explore whether MMP12 could affect the body weight of ApcMin/+ mice.ResultsMMP12 knockout led to weight gain and expansion of muscle fiber cross-sectional area (all mice had C57BL/6 background) in ApcMin/+ mice, while inhibiting MMP12 could suppress weight loss in ApcMin/+ mice. MMP12 was up-regulated in muscle tissues and peritoneal macrophages of ApcMin/+ mice. IL-6 in tumor cells and colorectal cancer patients is up-regulation. IL-6 stimulated MMP12 secretion of macrophage.ConclusionsMMP12 is essential for controlling body weight of Apc Min/+ mice. Our study shows that it exists the crosstalk between cancer cells and macrophages in muscle tissues that tumor cells secrete IL-6 inducing macrophages to up-regulate MMP12. This study may provide a new perspective of MMP12 in the treatment for weight loss induced by CAC.
Highlights
Colorectal cancer is a malignant gastrointestinal cancer, in which some advanced patients would develop cancer cachexia (CAC)
Since weight loss induced by CAC may be related to the wasting of skeletal muscle weight and fat weight [30], we hereby investigated whether weight gain in ApcMin/+mice caused by Matrix Metalloproteinases 12 (MMP12) knockout was due to a reduction in fat and skeletal muscle loss at 24 weeks old
A significant increase of approximately 4.5% in the muscle-to-body weight ratio was observed in ApcMin/+; MMP12−/− mice compared with A pcMin/+ mice (Fig. 1C)
Summary
Colorectal cancer is a malignant gastrointestinal cancer, in which some advanced patients would develop cancer cachexia (CAC). Upon studying the ApcMin/+ mouse model, we observed a marked decrease in weight gain beginning around week 15 Such a reduction in weight gain was rescued when ApcMin/+ mice were crossed with MMP12−/− mice, indicating that MMP12 has a role in age-related ApcMin/+-associated weight loss. Ongoing loss of body weight and skeletal muscle mass is a late outcome of nearly 80% of patients with different types of cancer, including pancreatic cancer, esophageal cancer, gastric cancer, lung cancer, liver cancer and CRC, and the mortality rate is as high as 30% [6,7,8]. A standard treatment of CRC is a combination of surgery, chemotherapy and radiotherapy, but it fails to significantly reduce mortality rate, which is closely related to CAC syndrome in patients with advanced CRC [10]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have